The HERCULES trial demonstrates tolebrutinib's potential to slow disability progression in non-relapsing secondary progressive multiple sclerosis, offering a new treatment option for patients with limited therapeutic choices.
Robert Fox, MD, FAAN
Advertisement
Articles by Robert Fox, MD, FAAN
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Vaccine Guidance Is Rapidly Changing—Here's What You Need to Know
2
FDA Approves First OTC Acetaminophen-Naproxen Combination for 12-Hour Pain Relief
3
What Real-World Data Show About Moving Patients From Humira to Biosimilars
4
Online GLP-1 Sellers Often Skip Clinician Oversight, Secret Shopper Study Finds
5